Ezetimibe vs Hyzetimibe

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atherosclerotic Cardiovascular Disease

Shared mechanism: NPC1L1 · full Atherosclerotic Cardiovascular Disease pipeline

Ezetimibe · Zetia

Marketed by Organon

Phase 3 in Atherosclerotic Cardiovascular Diseasesmall molecule
Reliable signal

NCT00092586 · Phase 3 · completed

This was a randomized, double-blind trial with a large sample (n=2,904) comparing ezetimibe plus a statin against a statin plus placebo. The primary endpoint, percent change in LDL cholesterol, was clearly met: ezetimibe produced a significantly larger reduction than placebo (p<.001).

Next expected readout: December 2026 · NCT04701242 (registry estimate)

Reported efficacy

Percent change in LDL-C: Percent change in LDL-C: ezetimibe+statin -25.8% vs placebo+statin -2.7%; treatment difference -23.1 percentage points (P<.001) (met)

Result source: NCT00092586

Hyzetimibe

Marketed by Zhejiang Hisun Pharmaceutical

Phase 3 in Atherosclerotic Cardiovascular Diseasesmall molecule
Partial signal

NCT03413462 · Phase 3 · completed

The trial randomized 374 participants to HS-25 or placebo and masked participants, investigators, and outcome assessors. Its primary endpoint was the surrogate measure of percent change in LDL-C, and because no primary-outcome results or statistical comparison are available, whether the endpoint was met is unknown.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Reported efficacy

Percent change of LDL-C (2,4,8,12 weeks): LDL-C percent change from baseline (primary endpoint, week 12): -16.39% (95% CI -19.04 to -13.74) with hyzetimibe (HS-25, referred to in this paper as hybutimibe) + atorvastatin vs -6.75% (95% CI -9.48 to -4.02) with atorvastatin alone, P<0.0001 (met)

Result source: NCT03433196

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEzetimibeHyzetimibe
LDL-C, % change-27.7% vs -0.9%−26.7 vs placebowk 12 · n 85NCT00867165
40 other results
  • -54% vs -53.8% 10 mg/20 mg · wk 6 · n 353 · Phase 3 · primary NCT01370590
  • -63.5% vs -57.4% 20 mg + 10 mg · wk 6 · n 204 · Phase 3 · primary NCT00525824
  • -26.7% vs -12.8% wk 6 · n 515 · Phase 3 · primary NCT00418834
  • -59.7% vs -57.4% 10 mg + 10 mg · wk 6 · n 210 · Phase 3 · primary NCT00525824
  • -58.9% vs -58.7% wk 6 · n 280 · Phase 3 · primary NCT01370603
  • -27.4% vs -11% wk 6 · n 277 · Phase 3 · primary NCT00276484
  • -18.7% vs -39.8% 10 mg · wk 12 · n 35 · Phase 3 · primary NCT02741245
  • -55.6% vs -44% 10 mg + 10 mg · wk 12 · n 68 · Phase 3 · primary NCT02550288
  • -59.2% vs -44% 10 mg + 20 mg · wk 12 · n 69 · Phase 3 · primary NCT02550288
  • -24.8% vs -13.8% 10 mg + 10 mg · wk 6 · n 120 · Phase 3 · primary NCT01154036
  • -54.6% vs -39.8% 10 mg + 2.5 mg · wk 12 · n 71 · Phase 3 · primary NCT02741245
  • -60.5% vs -39.8% 10 mg + 5.0 mg · wk 12 · n 72 · Phase 3 · primary NCT02741245
  • -30.8% vs -10.9% wk 6 · n 92 · Phase 3 · primary NCT00276458
  • -27.2% vs 0.5% wk 8 · n 90 · Phase 3 · secondary NCT00867165
  • -26.9% vs -3.0% wk 4 · n 90 · Phase 3 · secondary NCT00867165
  • -24.8% vs 0.2% wk 2 · n 91 · Phase 3 · secondary NCT00867165
  • -53.6% vs -46.4% 20 mg + 10 mg · wk 6 · n 199 · Phase 3 · secondary NCT00525824
  • -22.5% vs -17.9% wk 12 · n 516 · Phase 3 · secondary NCT00418834
  • -16.4% vs -8.4% 10 mg + 20 mg · wk 12 · n 124 · Phase 3 · secondary NCT01154036
  • -19.3% vs -8.4% 10 mg + 20 mg · wk 12 · n 231 · Phase 3 · secondary NCT01154036
  • -24% vs -6.1% 10 mg + 10 mg · wk 6 · n 121 · Phase 3 · secondary NCT00783263
  • -46.5% vs -46.4% 10 mg + 10 mg · wk 6 · n 206 · Phase 3 · secondary NCT00525824
  • -18.6% vs -6.1% 5 mg + 10 mg · wk 6 · n 98 · Phase 3 · secondary NCT00783263
  • 2.4% vs -8.4% 10 mg + 10 mg · wk 12 · n 28 · Phase 3 · secondary NCT01154036
  • -63.6% vs -3.1% bempedoic acid 180 mg, ezetimibe 10 mg, atorvastatin 20 mg · wk 6 · n 43 · Phase 2 · primary NCT03051100
  • -45.6% vs -0.2% wk 8 · n 24 · Phase 2 · primary NCT04770389
  • -52.0% vs -1.4% wk 8 · n 24 · Phase 2 · primary NCT04770389
  • -43.5% vs 1.4% wk 8 · n 27 · Phase 2 · primary NCT04770389
  • -44.4% vs -1.5% wk 8 · n 24 · Phase 2 · primary NCT04770389
  • -51.4% vs -2% wk 8 · n 24 · Phase 2 · primary NCT04770389
  • -44.1% vs -0.8% wk 8 · n 24 · Phase 2 · primary NCT04770389
  • -12.7% vs -0.2% wk 8 · n 25 · Phase 2 · secondary NCT04770389
  • -14.8% vs -1.4% wk 8 · n 25 · Phase 2 · secondary NCT04770389
  • -13.4% vs 1.4% wk 8 · n 28 · Phase 2 · secondary NCT04770389
  • -22.8% vs -1.8% wk 24 · n 74 · Phase 4 · secondary NCT01611883
  • -13.7% vs -1.5% wk 8 · n 23 · Phase 2 · secondary NCT04770389
  • -14.9% vs -2% wk 8 · n 23 · Phase 2 · secondary NCT04770389
  • -13.6% vs -0.8% wk 8 · n 23 · Phase 2 · secondary NCT04770389
  • -22.9% vs -1.0% wk 6 · n 24 · Phase 4 · secondary NCT00794677
  • -25.8% vs -2.7% Phase 3 · primary NCT00092586
-16.4% vs -6.8%avs atorvastatin alonewk 12NCT03433196
Non-HDL-C, % change-55.6% vs -51%−4.6 vs placebowk 12 · n 262NCT00639158
18 other results
  • -25.5% vs 0.3% wk 12 · n 85 · Phase 3 · secondary NCT00867165
  • -25.4% vs 1.1% wk 8 · n 90 · Phase 3 · secondary NCT00867165
  • -24.9% vs -0.3% wk 4 · n 90 · Phase 3 · secondary NCT00867165
  • -22.5% vs 1.6% wk 2 · n 91 · Phase 3 · secondary NCT00867165
  • -17.5% vs -6.3% 10 mg + 20 mg · wk 12 · n 124 · Phase 3 · secondary NCT01154036
  • -18.1% vs -6.3% 10 mg + 20 mg · wk 12 · n 231 · Phase 3 · secondary NCT01154036
  • -58.9% vs -52.4% 20 mg + 10 mg · wk 6 · n 204 · Phase 3 · secondary NCT00525824
  • -20% vs -15.8% wk 12 · n 516 · Phase 3 · secondary NCT00418834
  • -23.5% vs -11.2% wk 6 · n 515 · Phase 3 · secondary NCT00418834
  • -18% vs -11.1% 10 mg + 10 mg · wk 6 · n 120 · Phase 3 · secondary NCT01154036
  • -50.1% vs -50.2% 10 mg/20 mg · wk 6 · n 353 · Phase 3 · secondary NCT01370590
  • -54.6% vs -52.4% 10 mg + 10 mg · wk 6 · n 210 · Phase 3 · secondary NCT00525824
  • -55.4% vs -55.2% wk 6 · n 280 · Phase 3 · secondary NCT01370603
  • -23.3% vs -9% wk 6 · n 277 · Phase 3 · secondary NCT00276484
  • -26.7% vs -10.2% wk 6 · n 92 · Phase 3 · secondary NCT00276458
  • -0.5% vs -6.3% 10 mg + 10 mg · wk 12 · n 28 · Phase 3 · secondary NCT01154036
  • -21.3% vs -2.3% wk 24 · n 74 · Phase 4 · secondary NCT01611883
  • -22.7% vs -1.3% wk 6 · n 24 · Phase 4 · secondary NCT00794677
—Not posted · NCT03433196
ApoB, % change-49.1% vs -44.7%−4.4 vs placebowk 12 · n 248NCT00639158
17 other results
  • -21.7% vs -1.4% wk 12 · n 85 · Phase 3 · secondary NCT00867165
  • -12% vs -4.9% 10 mg + 20 mg · wk 12 · n 124 · Phase 3 · secondary NCT01154036
  • -14% vs -4.9% 10 mg + 20 mg · wk 12 · n 231 · Phase 3 · secondary NCT01154036
  • -12.1% vs -7.6% 10 mg + 10 mg · wk 6 · n 120 · Phase 3 · secondary NCT01154036
  • -42.6% vs -43.3% 10 mg/20 mg · wk 6 · n 352 · Phase 3 · secondary NCT01370590
  • -49.5% vs -44.2% 20 mg + 10 mg · wk 6 · n 199 · Phase 3 · secondary NCT00525824
  • -14% vs -10.8% wk 12 · n 511 · Phase 3 · secondary NCT00418834
  • -16.8% vs -7.7% wk 6 · n 507 · Phase 3 · secondary NCT00418834
  • -46.1% vs -44.2% 10 mg + 10 mg · wk 6 · n 206 · Phase 3 · secondary NCT00525824
  • -48.7% vs -48.3% wk 6 · n 278 · Phase 3 · secondary NCT01370603
  • -17.8% vs -7.7% wk 6 · n 275 · Phase 3 · secondary NCT00276484
  • -21.4% vs -7.7% wk 6 · n 89 · Phase 3 · secondary NCT00276458
  • -4% vs -4.9% 10 mg + 10 mg · wk 12 · n 27 · Phase 3 · secondary NCT01154036
  • -31.6% vs -1.2% wk 8 · n 24 · Phase 2 · secondary NCT04770389
  • -34.8% vs -0.9% wk 8 · n 24 · Phase 2 · secondary NCT04770389
  • -29.7% vs -0.1% wk 8 · n 27 · Phase 2 · secondary NCT04770389
  • -18.0% vs -2.6% wk 6 · n 24 · Phase 4 · secondary NCT00794677
—Not posted · NCT03433196
Lp(a), % change—Not posted · NCT03872232—Not posted · NCT03433196
3-point MACE (% with event)—Not posted · NCT03872232—Not posted · NCT03433196

LDL-C, % change

Ezetimibe
-27.7% vs -0.9%−26.7 vs placebowk 12 · n 85NCT00867165
40 other results
  • -54% vs -53.8% 10 mg/20 mg · wk 6 · n 353 · Phase 3 · primary NCT01370590
  • -63.5% vs -57.4% 20 mg + 10 mg · wk 6 · n 204 · Phase 3 · primary NCT00525824
  • -26.7% vs -12.8% wk 6 · n 515 · Phase 3 · primary NCT00418834
  • -59.7% vs -57.4% 10 mg + 10 mg · wk 6 · n 210 · Phase 3 · primary NCT00525824
  • -58.9% vs -58.7% wk 6 · n 280 · Phase 3 · primary NCT01370603
  • -27.4% vs -11% wk 6 · n 277 · Phase 3 · primary NCT00276484
  • -18.7% vs -39.8% 10 mg · wk 12 · n 35 · Phase 3 · primary NCT02741245
  • -55.6% vs -44% 10 mg + 10 mg · wk 12 · n 68 · Phase 3 · primary NCT02550288
  • -59.2% vs -44% 10 mg + 20 mg · wk 12 · n 69 · Phase 3 · primary NCT02550288
  • -24.8% vs -13.8% 10 mg + 10 mg · wk 6 · n 120 · Phase 3 · primary NCT01154036
  • -54.6% vs -39.8% 10 mg + 2.5 mg · wk 12 · n 71 · Phase 3 · primary NCT02741245
  • -60.5% vs -39.8% 10 mg + 5.0 mg · wk 12 · n 72 · Phase 3 · primary NCT02741245
  • -30.8% vs -10.9% wk 6 · n 92 · Phase 3 · primary NCT00276458
  • -27.2% vs 0.5% wk 8 · n 90 · Phase 3 · secondary NCT00867165
  • -26.9% vs -3.0% wk 4 · n 90 · Phase 3 · secondary NCT00867165
  • -24.8% vs 0.2% wk 2 · n 91 · Phase 3 · secondary NCT00867165
  • -53.6% vs -46.4% 20 mg + 10 mg · wk 6 · n 199 · Phase 3 · secondary NCT00525824
  • -22.5% vs -17.9% wk 12 · n 516 · Phase 3 · secondary NCT00418834
  • -16.4% vs -8.4% 10 mg + 20 mg · wk 12 · n 124 · Phase 3 · secondary NCT01154036
  • -19.3% vs -8.4% 10 mg + 20 mg · wk 12 · n 231 · Phase 3 · secondary NCT01154036
  • -24% vs -6.1% 10 mg + 10 mg · wk 6 · n 121 · Phase 3 · secondary NCT00783263
  • -46.5% vs -46.4% 10 mg + 10 mg · wk 6 · n 206 · Phase 3 · secondary NCT00525824
  • -18.6% vs -6.1% 5 mg + 10 mg · wk 6 · n 98 · Phase 3 · secondary NCT00783263
  • 2.4% vs -8.4% 10 mg + 10 mg · wk 12 · n 28 · Phase 3 · secondary NCT01154036
  • -63.6% vs -3.1% bempedoic acid 180 mg, ezetimibe 10 mg, atorvastatin 20 mg · wk 6 · n 43 · Phase 2 · primary NCT03051100
  • -45.6% vs -0.2% wk 8 · n 24 · Phase 2 · primary NCT04770389
  • -52.0% vs -1.4% wk 8 · n 24 · Phase 2 · primary NCT04770389
  • -43.5% vs 1.4% wk 8 · n 27 · Phase 2 · primary NCT04770389
  • -44.4% vs -1.5% wk 8 · n 24 · Phase 2 · primary NCT04770389
  • -51.4% vs -2% wk 8 · n 24 · Phase 2 · primary NCT04770389
  • -44.1% vs -0.8% wk 8 · n 24 · Phase 2 · primary NCT04770389
  • -12.7% vs -0.2% wk 8 · n 25 · Phase 2 · secondary NCT04770389
  • -14.8% vs -1.4% wk 8 · n 25 · Phase 2 · secondary NCT04770389
  • -13.4% vs 1.4% wk 8 · n 28 · Phase 2 · secondary NCT04770389
  • -22.8% vs -1.8% wk 24 · n 74 · Phase 4 · secondary NCT01611883
  • -13.7% vs -1.5% wk 8 · n 23 · Phase 2 · secondary NCT04770389
  • -14.9% vs -2% wk 8 · n 23 · Phase 2 · secondary NCT04770389
  • -13.6% vs -0.8% wk 8 · n 23 · Phase 2 · secondary NCT04770389
  • -22.9% vs -1.0% wk 6 · n 24 · Phase 4 · secondary NCT00794677
  • -25.8% vs -2.7% Phase 3 · primary NCT00092586
Hyzetimibe
-16.4% vs -6.8%avs atorvastatin alonewk 12NCT03433196

Non-HDL-C, % change

Ezetimibe
-55.6% vs -51%−4.6 vs placebowk 12 · n 262NCT00639158
18 other results
  • -25.5% vs 0.3% wk 12 · n 85 · Phase 3 · secondary NCT00867165
  • -25.4% vs 1.1% wk 8 · n 90 · Phase 3 · secondary NCT00867165
  • -24.9% vs -0.3% wk 4 · n 90 · Phase 3 · secondary NCT00867165
  • -22.5% vs 1.6% wk 2 · n 91 · Phase 3 · secondary NCT00867165
  • -17.5% vs -6.3% 10 mg + 20 mg · wk 12 · n 124 · Phase 3 · secondary NCT01154036
  • -18.1% vs -6.3% 10 mg + 20 mg · wk 12 · n 231 · Phase 3 · secondary NCT01154036
  • -58.9% vs -52.4% 20 mg + 10 mg · wk 6 · n 204 · Phase 3 · secondary NCT00525824
  • -20% vs -15.8% wk 12 · n 516 · Phase 3 · secondary NCT00418834
  • -23.5% vs -11.2% wk 6 · n 515 · Phase 3 · secondary NCT00418834
  • -18% vs -11.1% 10 mg + 10 mg · wk 6 · n 120 · Phase 3 · secondary NCT01154036
  • -50.1% vs -50.2% 10 mg/20 mg · wk 6 · n 353 · Phase 3 · secondary NCT01370590
  • -54.6% vs -52.4% 10 mg + 10 mg · wk 6 · n 210 · Phase 3 · secondary NCT00525824
  • -55.4% vs -55.2% wk 6 · n 280 · Phase 3 · secondary NCT01370603
  • -23.3% vs -9% wk 6 · n 277 · Phase 3 · secondary NCT00276484
  • -26.7% vs -10.2% wk 6 · n 92 · Phase 3 · secondary NCT00276458
  • -0.5% vs -6.3% 10 mg + 10 mg · wk 12 · n 28 · Phase 3 · secondary NCT01154036
  • -21.3% vs -2.3% wk 24 · n 74 · Phase 4 · secondary NCT01611883
  • -22.7% vs -1.3% wk 6 · n 24 · Phase 4 · secondary NCT00794677
Hyzetimibe
—Not posted · NCT03433196

ApoB, % change

Ezetimibe
-49.1% vs -44.7%−4.4 vs placebowk 12 · n 248NCT00639158
17 other results
  • -21.7% vs -1.4% wk 12 · n 85 · Phase 3 · secondary NCT00867165
  • -12% vs -4.9% 10 mg + 20 mg · wk 12 · n 124 · Phase 3 · secondary NCT01154036
  • -14% vs -4.9% 10 mg + 20 mg · wk 12 · n 231 · Phase 3 · secondary NCT01154036
  • -12.1% vs -7.6% 10 mg + 10 mg · wk 6 · n 120 · Phase 3 · secondary NCT01154036
  • -42.6% vs -43.3% 10 mg/20 mg · wk 6 · n 352 · Phase 3 · secondary NCT01370590
  • -49.5% vs -44.2% 20 mg + 10 mg · wk 6 · n 199 · Phase 3 · secondary NCT00525824
  • -14% vs -10.8% wk 12 · n 511 · Phase 3 · secondary NCT00418834
  • -16.8% vs -7.7% wk 6 · n 507 · Phase 3 · secondary NCT00418834
  • -46.1% vs -44.2% 10 mg + 10 mg · wk 6 · n 206 · Phase 3 · secondary NCT00525824
  • -48.7% vs -48.3% wk 6 · n 278 · Phase 3 · secondary NCT01370603
  • -17.8% vs -7.7% wk 6 · n 275 · Phase 3 · secondary NCT00276484
  • -21.4% vs -7.7% wk 6 · n 89 · Phase 3 · secondary NCT00276458
  • -4% vs -4.9% 10 mg + 10 mg · wk 12 · n 27 · Phase 3 · secondary NCT01154036
  • -31.6% vs -1.2% wk 8 · n 24 · Phase 2 · secondary NCT04770389
  • -34.8% vs -0.9% wk 8 · n 24 · Phase 2 · secondary NCT04770389
  • -29.7% vs -0.1% wk 8 · n 27 · Phase 2 · secondary NCT04770389
  • -18.0% vs -2.6% wk 6 · n 24 · Phase 4 · secondary NCT00794677
Hyzetimibe
—Not posted · NCT03433196

Lp(a), % change

Ezetimibe
—Not posted · NCT03872232
Hyzetimibe
—Not posted · NCT03433196

3-point MACE (% with event)

Ezetimibe
—Not posted · NCT03872232
Hyzetimibe
—Not posted · NCT03433196
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Ezetimibe: 4 of 4 rows · Hyzetimibe: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricEzetimibeHyzetimibe
Dropout rate
1.3%a
NCT01611883 · Phase 4 · registry result, not featured evidence
show 43 more results
—
NCT00701727 · Phase 4 · registry result, not featured evidence
20%10 mg
NCT00319449 · Phase 4 · registry result, not featured evidence
4.4%Ezetimibe 10 mg + Rosuvastatin 2.5
NCT02748057 · Phase 3 · registry result, not featured evidence · combination
9.5%Ezetimibe 10 mg + Rosuvastatin 5.0
NCT02748057 · Phase 3 · registry result, not featured evidence · combination
0%10 mg
NCT02741245 · Phase 3 · registry result, not featured evidence
5.6%10 mg + 2.5 mg
NCT02741245 · Phase 3 · registry result, not featured evidence · combination
2.8%10 mg + 5.0 mg
NCT02741245 · Phase 3 · registry result, not featured evidence · combination
4.4%10 mg + 10 mg
NCT02550288 · Phase 3 · registry result, not featured evidence · combination
4.3%10 mg + 20 mg
NCT02550288 · Phase 3 · registry result, not featured evidence · combination
2.5%10 mg + 10 mg
NCT01154036 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 20 mg
NCT01154036 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 20 mg
NCT01154036 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 10 mg
NCT01154036 · Phase 3 · registry result, not featured evidence · combination
—
NCT01370603 · Phase 3 · registry result, not featured evidence
4.3%
NCT00867165 · Phase 3 · registry result, not featured evidence
—10 mg/20 mg
NCT01370590 · Phase 3 · registry result, not featured evidence
—10 mg + 10 mg
NCT00783263 · Phase 3 · registry result, not featured evidence · combination
2.5%10 mg + 10 mg
NCT00783263 · Phase 3 · registry result, not featured evidence · combination
—5 mg + 10 mg
NCT00783263 · Phase 3 · registry result, not featured evidence · combination
4%5 mg + 10 mg
NCT00783263 · Phase 3 · registry result, not featured evidence · combination
21.9%Ezetimibe + Atorvastatin
NCT00654095 · Phase 3 · registry result, not featured evidence · combination
—Ezetimibe+Atorvastatin
NCT00654095 · Phase 3 · registry result, not featured evidence · combination
4.4%
NCT00418834 · Phase 3 · registry result, not featured evidence · combination
9.6%
NCT00639158 · Phase 3 · registry result, not featured evidence · combination
—20 mg
NCT00525824 · Phase 3 · registry result, not featured evidence
—10 mg
NCT00525824 · Phase 3 · registry result, not featured evidence
13.1%20 mg + 10 mg
NCT00525824 · Phase 3 · registry result, not featured evidence · combination
—20 mg + 10 mg
NCT00525824 · Phase 3 · registry result, not featured evidence · combination
8.9%10 mg + 10 mg
NCT00525824 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 10 mg
NCT00525824 · Phase 3 · registry result, not featured evidence · combination
3.1%
NCT00276484 · Phase 3 · registry result, not featured evidence · combination
6.1%
NCT00276458 · Phase 3 · registry result, not featured evidence · combination
—
NCT00101439 · Phase 3 · registry result, not featured evidence
18.5%Combination Therapy
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
17.2%Ezetimibe Monotherapy
NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy
0%bempedoic acid 180 mg, ezetimibe 10 mg, atorvastatin 20 mg
NCT03051100 · Phase 2 · registry result, not featured evidence · combination
—800 mg
NCT01218204 · Phase 2 · registry result, not featured evidence
—300 mg
NCT01218204 · Phase 2 · registry result, not featured evidence
—100 mg
NCT01218204 · Phase 2 · registry result, not featured evidence
—80 mg + 800 mg
NCT01218204 · Phase 2 · registry result, not featured evidence · combination
—10 mg + 100 mg
NCT01218204 · Phase 2 · registry result, not featured evidence · combination
—10 mg + 300 mg
NCT01218204 · Phase 2 · registry result, not featured evidence · combination
—10 mg + 800 mg
NCT01218204 · Phase 2 · registry result, not featured evidence · combination
—
Discontinued due to AEs
1.3%a
NCT01611883 · Phase 4 · registry result, not featured evidence
show 43 more results
—
NCT00701727 · Phase 4 · registry result, not featured evidence
—10 mg
NCT00319449 · Phase 4 · registry result, not featured evidence
0.9%Ezetimibe 10 mg + Rosuvastatin 2.5
NCT02748057 · Phase 3 · registry result, not featured evidence · combination
0%Ezetimibe 10 mg + Rosuvastatin 5.0
NCT02748057 · Phase 3 · registry result, not featured evidence · combination
0%10 mg
NCT02741245 · Phase 3 · registry result, not featured evidence
2.8%10 mg + 2.5 mg
NCT02741245 · Phase 3 · registry result, not featured evidence · combination
2.8%10 mg + 5.0 mg
NCT02741245 · Phase 3 · registry result, not featured evidence · combination
0%10 mg + 10 mg
NCT02550288 · Phase 3 · registry result, not featured evidence · combination
0%10 mg + 20 mg
NCT02550288 · Phase 3 · registry result, not featured evidence · combination
0.8%10 mg + 10 mg
NCT01154036 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 20 mg
NCT01154036 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 20 mg
NCT01154036 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 10 mg
NCT01154036 · Phase 3 · registry result, not featured evidence · combination
—
NCT01370603 · Phase 3 · registry result, not featured evidence
3.2%
NCT00867165 · Phase 3 · registry result, not featured evidence
—10 mg/20 mg
NCT01370590 · Phase 3 · registry result, not featured evidence
—10 mg + 10 mg
NCT00783263 · Phase 3 · registry result, not featured evidence · combination
1.6%10 mg + 10 mg
NCT00783263 · Phase 3 · registry result, not featured evidence · combination
—5 mg + 10 mg
NCT00783263 · Phase 3 · registry result, not featured evidence · combination
3%5 mg + 10 mg
NCT00783263 · Phase 3 · registry result, not featured evidence · combination
10.3%Ezetimibe + Atorvastatin
NCT00654095 · Phase 3 · registry result, not featured evidence · combination
—Ezetimibe+Atorvastatin
NCT00654095 · Phase 3 · registry result, not featured evidence · combination
3%
NCT00418834 · Phase 3 · registry result, not featured evidence · combination
—
NCT00639158 · Phase 3 · registry result, not featured evidence · combination
—20 mg
NCT00525824 · Phase 3 · registry result, not featured evidence
—10 mg
NCT00525824 · Phase 3 · registry result, not featured evidence
5.1%20 mg + 10 mg
NCT00525824 · Phase 3 · registry result, not featured evidence · combination
—20 mg + 10 mg
NCT00525824 · Phase 3 · registry result, not featured evidence · combination
3.3%10 mg + 10 mg
NCT00525824 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 10 mg
NCT00525824 · Phase 3 · registry result, not featured evidence · combination
1.4%
NCT00276484 · Phase 3 · registry result, not featured evidence · combination
0%
NCT00276458 · Phase 3 · registry result, not featured evidence · combination
—
NCT00101439 · Phase 3 · registry result, not featured evidence
7.4%Combination Therapy
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
3.4%Ezetimibe Monotherapy
NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy
—bempedoic acid 180 mg, ezetimibe 10 mg, atorvastatin 20 mg
NCT03051100 · Phase 2 · registry result, not featured evidence · combination
—800 mg
NCT01218204 · Phase 2 · registry result, not featured evidence
—300 mg
NCT01218204 · Phase 2 · registry result, not featured evidence
—100 mg
NCT01218204 · Phase 2 · registry result, not featured evidence
—80 mg + 800 mg
NCT01218204 · Phase 2 · registry result, not featured evidence · combination
—10 mg + 100 mg
NCT01218204 · Phase 2 · registry result, not featured evidence · combination
—10 mg + 300 mg
NCT01218204 · Phase 2 · registry result, not featured evidence · combination
—10 mg + 800 mg
NCT01218204 · Phase 2 · registry result, not featured evidence · combination
—
Serious AEs
2.7%a
NCT01611883 · Phase 4 · registry result, not featured evidence
show 43 more results
0%
NCT00701727 · Phase 4 · registry result, not featured evidence
10%10 mg
NCT00319449 · Phase 4 · registry result, not featured evidence
1.8%Ezetimibe 10 mg + Rosuvastatin 2.5
NCT02748057 · Phase 3 · registry result, not featured evidence · combination
4.8%Ezetimibe 10 mg + Rosuvastatin 5.0
NCT02748057 · Phase 3 · registry result, not featured evidence · combination
0%10 mg
NCT02741245 · Phase 3 · registry result, not featured evidence
0%10 mg + 2.5 mg
NCT02741245 · Phase 3 · registry result, not featured evidence · combination
0%10 mg + 5.0 mg
NCT02741245 · Phase 3 · registry result, not featured evidence · combination
0%10 mg + 10 mg
NCT02550288 · Phase 3 · registry result, not featured evidence · combination
0%10 mg + 20 mg
NCT02550288 · Phase 3 · registry result, not featured evidence · combination
0%10 mg + 10 mg
NCT01154036 · Phase 3 · registry result, not featured evidence · combination
1.6%10 mg + 20 mg
NCT01154036 · Phase 3 · registry result, not featured evidence · combination
2.2%10 mg + 20 mg
NCT01154036 · Phase 3 · registry result, not featured evidence · combination
0%10 mg + 10 mg
NCT01154036 · Phase 3 · registry result, not featured evidence · combination
1%
NCT01370603 · Phase 3 · registry result, not featured evidence
2.2%
NCT00867165 · Phase 3 · registry result, not featured evidence
0.5%10 mg/20 mg
NCT01370590 · Phase 3 · registry result, not featured evidence
0%10 mg + 10 mg
NCT00783263 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 10 mg
NCT00783263 · Phase 3 · registry result, not featured evidence · combination
0%5 mg + 10 mg
NCT00783263 · Phase 3 · registry result, not featured evidence · combination
—5 mg + 10 mg
NCT00783263 · Phase 3 · registry result, not featured evidence · combination
—Ezetimibe + Atorvastatin
NCT00654095 · Phase 3 · registry result, not featured evidence · combination
7.5%Ezetimibe+Atorvastatin
NCT00654095 · Phase 3 · registry result, not featured evidence · combination
—
NCT00418834 · Phase 3 · registry result, not featured evidence · combination
1.1%
NCT00639158 · Phase 3 · registry result, not featured evidence · combination
—20 mg
NCT00525824 · Phase 3 · registry result, not featured evidence
—10 mg
NCT00525824 · Phase 3 · registry result, not featured evidence
—20 mg + 10 mg
NCT00525824 · Phase 3 · registry result, not featured evidence · combination
—20 mg + 10 mg
NCT00525824 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 10 mg
NCT00525824 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 10 mg
NCT00525824 · Phase 3 · registry result, not featured evidence · combination
—
NCT00276484 · Phase 3 · registry result, not featured evidence · combination
0%
NCT00276458 · Phase 3 · registry result, not featured evidence · combination
0%
NCT00101439 · Phase 3 · registry result, not featured evidence
0%Combination Therapy
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
7.1%Ezetimibe Monotherapy
NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy
0%bempedoic acid 180 mg, ezetimibe 10 mg, atorvastatin 20 mg
NCT03051100 · Phase 2 · registry result, not featured evidence · combination
0%800 mg
NCT01218204 · Phase 2 · registry result, not featured evidence
0%300 mg
NCT01218204 · Phase 2 · registry result, not featured evidence
0%100 mg
NCT01218204 · Phase 2 · registry result, not featured evidence
0%80 mg + 800 mg
NCT01218204 · Phase 2 · registry result, not featured evidence · combination
0%10 mg + 100 mg
NCT01218204 · Phase 2 · registry result, not featured evidence · combination
0%10 mg + 300 mg
NCT01218204 · Phase 2 · registry result, not featured evidence · combination
0%10 mg + 800 mg
NCT01218204 · Phase 2 · registry result, not featured evidence · combination
—
Most frequent reported AEs
a
nasopharyngitis 14.7% (placebo 16.9%)
type 2 diabetes mellitus 9.3% (placebo 7.8%)
hypoglycaemia 2.7% (placebo 9.1%)
NCT01611883 · Phase 4 · registry result, not featured evidence
show 29 more results
constipation 9.7% (placebo 9.7%)
contusion 6.5% (placebo 0%)
diarrhoea 6.5% (placebo 6.5%)
NCT00701727 · Phase 4 · registry result, not featured evidence
10 mg
arthralgia 10% (placebo 0%)
headache 10% (placebo 0%)
myalgia 10% (placebo 0%)
NCT00319449 · Phase 4 · registry result, not featured evidence
nasopharyngitis 36%
back pain 7.9%
gastroenteritis 7%
NCT02748057 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 38.1%
contusion 9.5%
liver function test abnormal 9.5%
NCT02748057 · Phase 3 · registry result, not featured evidence · combination
10 mg
nasopharyngitis 17.1%
NCT02741245 · Phase 3 · registry result, not featured evidence
10 mg + 2.5 mg
nasopharyngitis 8.5%
NCT02741245 · Phase 3 · registry result, not featured evidence · combination
10 mg + 5.0 mg
nasopharyngitis 9.7%
NCT02741245 · Phase 3 · registry result, not featured evidence · combination
10 mg + 10 mg
nasopharyngitis 14.7%
alanine aminotransferase increased 1.5%
NCT02550288 · Phase 3 · registry result, not featured evidence · combination
10 mg + 20 mg
nasopharyngitis 17.4%
alanine aminotransferase increased 5.8%
NCT02550288 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 10.9% (placebo 11.1%)
upper respiratory tract infection 7.6% (placebo 2.2%)
influenza 5.4% (placebo 6.7%)
NCT00867165 · Phase 3 · registry result, not featured evidence
nasopharyngitis 36.3%
alanine aminotransferase increased 32.9%
c-reactive protein increased 21.2%
NCT00654095 · Phase 3 · registry result, not featured evidence · combination
constipation 1.3%
headache 1.3%
upper respiratory tract infection 1.3%
NCT00418834 · Phase 3 · registry result, not featured evidence · combination
muscle spasms 3.7% (placebo 3.3%)
diarrhea 3.3% (placebo 2.2%)
myalgia 2.6% (placebo 3.7%)
NCT00639158 · Phase 3 · registry result, not featured evidence · combination
20 mg
myalgia 4.7%
dizziness 2.4%
nausea 2.4%
NCT00525824 · Phase 3 · registry result, not featured evidence
10 mg
arthralgia 2.3%
myalgia 2.3%
headache 1.9%
NCT00525824 · Phase 3 · registry result, not featured evidence
20 mg + 10 mg
myalgia 2.6%
nasopharyngitis 2.6%
influenza 2.1%
NCT00525824 · Phase 3 · registry result, not featured evidence · combination
10 mg + 10 mg
myalgia 2%
bronchitis 1.5%
headache 1.5%
NCT00525824 · Phase 3 · registry result, not featured evidence · combination
bronchitis 1.4%
headache 1.4%
nasopharyngitis 1.4%
NCT00276484 · Phase 3 · registry result, not featured evidence · combination
fatigue 2.1%
nasopharyngitis 2.1%
vertigo 2.1%
NCT00276458 · Phase 3 · registry result, not featured evidence · combination
diarrhoea 7.4% (placebo 0%)
abdominal pain 3.7% (placebo 0%)
back pain 3.7% (placebo 0%)
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 7.1% (placebo 0%)
headache 7.1% (placebo 3.6%)
bursitis 3.6% (placebo 0%)
NCT04770389 · Phase 2 · registry result, not featured evidence · monotherapy
bempedoic acid 180 mg, ezetimibe 10 mg, atorvastatin 20 mg
diarrhoea 4.7% (placebo 0%)
fatigue 4.7% (placebo 0%)
headache 4.7% (placebo 5%)
NCT03051100 · Phase 2 · registry result, not featured evidence · combination
800 mg
headache 15.4% (placebo 18.2%)
blood calcium decreased 7.7% (placebo 0%)
constipation 7.7% (placebo 0%)
NCT01218204 · Phase 2 · registry result, not featured evidence
300 mg
nausea 33.3% (placebo 0%)
constipation 16.7% (placebo 0%)
contusion 16.7% (placebo 0%)
NCT01218204 · Phase 2 · registry result, not featured evidence
100 mg
headache 18.2% (placebo 18.2%)
back pain 9.1% (placebo 0%)
cough 9.1% (placebo 0%)
NCT01218204 · Phase 2 · registry result, not featured evidence
80 mg + 800 mg
dizziness 16.7% (placebo 0%)
headache 16.7% (placebo 18.2%)
abdominal pain upper 8.3% (placebo 0%)
NCT01218204 · Phase 2 · registry result, not featured evidence · combination
10 mg + 100 mg
headache 27.3% (placebo 18.2%)
rash 18.2% (placebo 0%)
blood creatine phosphokinase increased 9.1% (placebo 0%)
NCT01218204 · Phase 2 · registry result, not featured evidence · combination
10 mg + 300 mg
diarrhoea 9.1% (placebo 9.1%)
headache 9.1% (placebo 18.2%)
rhinorrhoea 9.1% (placebo 0%)
NCT01218204 · Phase 2 · registry result, not featured evidence · combination
10 mg + 800 mg
back pain 9.1% (placebo 0%)
fatigue 9.1% (placebo 9.1%)
headache 9.1% (placebo 18.2%)
NCT01218204 · Phase 2 · registry result, not featured evidence · combination
—

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Ezetimibe

HbA1c 0.22% (n=69) vs 0.14% (n=75) placebo @ 24wk
absolute change · percentage points
NCT01611883 · Phase 4 · registry result, not featured evidence
Fasting Plasma Glucose 0.37 vs 0.63 placebo mmol/L @ 24wk
absolute change · mmol/L
NCT01611883 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 6.6 mg/dL as posted
Total Cholesterol -13.6% (n=120) vs -6.3% (n=480) Atorvastatin @ 6wk10 mg + 10 mg
percent change · % of baseline
NCT01154036 · Phase 3 · registry result, not featured evidence · combination
show 15 more results
-10.2% (n=124) vs -2.9% (n=124) Atorvastatin @ 12wk10 mg + 20 mg
NCT01154036 · Phase 3 · registry result, not featured evidence · combination
-13.1% (n=231) vs -2.9% (n=124) Atorvastatin @ 12wk10 mg + 20 mg
NCT01154036 · Phase 3 · registry result, not featured evidence · combination
2.2% (n=28) vs -2.9% (n=124) Atorvastatin @ 12wk10 mg + 10 mg
NCT01154036 · Phase 3 · registry result, not featured evidence · combination
-38.1% (n=353) vs -38.5% (n=346) Ezetimibe and Atorvastatin @ 6wk10 mg/20 mg
NCT01370590 · Phase 3 · registry result, not featured evidence
-46.63% (n=204) vs -39.56% (n=199) Simvastatin + Ezetimibe @ 6wk20 mg + 10 mg
NCT00525824 · Phase 3 · registry result, not featured evidence · combination
-15.9% (n=515) vs -8% (n=516) Atorva @ 6wk
NCT00418834 · Phase 3 · registry result, not featured evidence · combination
-13.6% (n=516) vs -11.6% (n=509) Atorva @ 12wk
NCT00418834 · Phase 3 · registry result, not featured evidence · combination
-43% (n=210) vs -39.56% (n=199) Simvastatin + Ezetimibe @ 6wk10 mg + 10 mg
NCT00525824 · Phase 3 · registry result, not featured evidence · combination
-15.01% (n=74) vs -1.47% (n=76) placebo @ 24wk
NCT01611883 · Phase 4 · registry result, not featured evidence
-43% (n=280) vs -42.9% (n=280) Ezetimibe and Atorvastatin @ 6wk
NCT01370603 · Phase 3 · registry result, not featured evidence
-20.74% (n=85) vs 0.19% (n=42) placebo @ 12wk
NCT00867165 · Phase 3 · registry result, not featured evidence
-18.69% (n=91) vs 1.4% (n=43) placebo @ 2wk
NCT00867165 · Phase 3 · registry result, not featured evidence
-20.57% (n=90) vs -0.29% (n=43) placebo @ 4wk
NCT00867165 · Phase 3 · registry result, not featured evidence
-20.84% (n=90) vs 0.54% (n=44) placebo @ 8wk
NCT00867165 · Phase 3 · registry result, not featured evidence
-16.9% (n=277) vs -6.9% (n=279) Atorvastatin @ 6wk
NCT00276484 · Phase 3 · registry result, not featured evidence · combination
Triglycerides -6% (n=119) vs -3.9% (n=471) Atorvastatin @ 6wk10 mg + 10 mg
percent change · % of baseline
NCT01154036 · Phase 3 · registry result, not featured evidence · combination
show 15 more results
-5.9% (n=120) vs -3.1% (n=123) Atorvastatin @ 12wk10 mg + 20 mg
NCT01154036 · Phase 3 · registry result, not featured evidence · combination
-10.2% (n=228) vs -3.1% (n=123) Atorvastatin @ 12wk10 mg + 20 mg
NCT01154036 · Phase 3 · registry result, not featured evidence · combination
NA vs -3.1% (n=123) Atorvastatin @ 12wk10 mg + 10 mg
NCT01154036 · Phase 3 · registry result, not featured evidence · combination
-57.3% (n=262) vs -39.7% (n=262) placebo @ 12wk
NCT00639158 · Phase 3 · registry result, not featured evidence · combination
-35% (n=204) vs -22.95% (n=199) Simvastatin + Ezetimibe @ 6wk20 mg + 10 mg
NCT00525824 · Phase 3 · registry result, not featured evidence · combination
-12.9% (n=515) vs -5.7% (n=516) Atorva @ 6wk
NCT00418834 · Phase 3 · registry result, not featured evidence · combination
-11.8% (n=516) vs -8.5% (n=509) Atorva @ 12wk
NCT00418834 · Phase 3 · registry result, not featured evidence · combination
-28.85% (n=210) vs -22.95% (n=199) Simvastatin + Ezetimibe @ 6wk10 mg + 10 mg
NCT00525824 · Phase 3 · registry result, not featured evidence · combination
-7.52% (n=74) vs 3.83% (n=76) placebo @ 24wk
NCT01611883 · Phase 4 · registry result, not featured evidence
-36.2% (n=280) vs -36.2% (n=280) Ezetimibe and Atorvastatin @ 6wk
NCT01370603 · Phase 3 · registry result, not featured evidence
-6.23% (n=85) vs 8.44% (n=42) placebo @ 12wk
NCT00867165 · Phase 3 · registry result, not featured evidence
-3.9% (n=91) vs 5.83% (n=43) placebo @ 2wk
NCT00867165 · Phase 3 · registry result, not featured evidence
-5.54% (n=90) vs 9.65% (n=43) placebo @ 4wk
NCT00867165 · Phase 3 · registry result, not featured evidence
-9.99% (n=90) vs -1.38% (n=44) placebo @ 8wk
NCT00867165 · Phase 3 · registry result, not featured evidence
-12.3% (n=277) vs -5.9% (n=279) Atorvastatin @ 6wk
NCT00276484 · Phase 3 · registry result, not featured evidence · combination
HDL-C 0.9% (n=120) vs -1.3% (n=480) Atorvastatin @ 6wk10 mg + 10 mg
percent change · % of baseline
NCT01154036 · Phase 3 · registry result, not featured evidence · combination
show 18 more results
0.9% (n=124) vs 1% (n=124) Atorvastatin @ 12wk10 mg + 20 mg
NCT01154036 · Phase 3 · registry result, not featured evidence · combination
-0.8% (n=231) vs 1% (n=124) Atorvastatin @ 12wk10 mg + 20 mg
NCT01154036 · Phase 3 · registry result, not featured evidence · combination
0% (n=28) vs 1% (n=124) Atorvastatin @ 12wk10 mg + 10 mg
NCT01154036 · Phase 3 · registry result, not featured evidence · combination
5.4% (n=353) vs 4.6% (n=346) Ezetimibe and Atorvastatin @ 6wk10 mg/20 mg
NCT01370590 · Phase 3 · registry result, not featured evidence
13% (n=262) vs 4.2% (n=262) placebo @ 12wk
NCT00639158 · Phase 3 · registry result, not featured evidence · combination
7.46% (n=204) vs 3.92% (n=199) Simvastatin + Ezetimibe @ 6wk20 mg + 10 mg
NCT00525824 · Phase 3 · registry result, not featured evidence · combination
2.5% (n=515) vs 0.7% (n=515) Atorva @ 6wk
NCT00418834 · Phase 3 · registry result, not featured evidence · combination
2.4% (n=516) vs -0.8% (n=509) Atorva @ 12wk
NCT00418834 · Phase 3 · registry result, not featured evidence · combination
6.41% (n=210) vs 3.92% (n=199) Simvastatin + Ezetimibe @ 6wk10 mg + 10 mg
NCT00525824 · Phase 3 · registry result, not featured evidence · combination
3.86% (n=74) vs 1.41% (n=76) placebo @ 24wk
NCT01611883 · Phase 4 · registry result, not featured evidence
-1.936% (n=24) vs -7.333% (n=24) placebo @ 6wk
NCT00794677 · Phase 4 · registry result, not featured evidence
2.3% (n=280) vs 2.6% (n=280) Ezetimibe and Atorvastatin @ 6wk
NCT01370603 · Phase 3 · registry result, not featured evidence
2.11% (n=85) vs 1.41% (n=42) placebo @ 12wk
NCT00867165 · Phase 3 · registry result, not featured evidence
0.01% (n=91) vs 0.96% (n=43) placebo @ 2wk
NCT00867165 · Phase 3 · registry result, not featured evidence
0.86% (n=90) vs 0.33% (n=43) placebo @ 4wk
NCT00867165 · Phase 3 · registry result, not featured evidence
1.41% (n=90) vs -0.52% (n=44) placebo @ 8wk
NCT00867165 · Phase 3 · registry result, not featured evidence
-0.5% (n=277) vs -1% (n=279) Atorvastatin @ 6wk
NCT00276484 · Phase 3 · registry result, not featured evidence · combination
3.2% (n=92) vs 0.8% (n=92) Atorvastatin @ 6wk
NCT00276458 · Phase 3 · registry result, not featured evidence · combination
Non-HDL-C -18% (n=120) vs -7.9% (n=480) Atorvastatin @ 6wk10 mg + 10 mg
percent change · % of baseline
NCT01154036 · Phase 3 · registry result, not featured evidence · combination
show 18 more results
-17.5% (n=124) vs -5.5% (n=124) Atorvastatin @ 12wk10 mg + 20 mg
NCT01154036 · Phase 3 · registry result, not featured evidence · combination
-18.1% (n=231) vs -5.5% (n=124) Atorvastatin @ 12wk10 mg + 20 mg
NCT01154036 · Phase 3 · registry result, not featured evidence · combination
-0.5% (n=28) vs -5.5% (n=124) Atorvastatin @ 12wk10 mg + 10 mg
NCT01154036 · Phase 3 · registry result, not featured evidence · combination
-50.1% (n=353) vs -50.2% (n=346) Ezetimibe and Atorvastatin @ 6wk10 mg/20 mg
NCT01370590 · Phase 3 · registry result, not featured evidence
-55.6% (n=262) vs -51% (n=262) placebo @ 12wk
NCT00639158 · Phase 3 · registry result, not featured evidence · combination
-58.91% (n=204) vs -49.93% (n=199) Simvastatin + Ezetimibe @ 6wk20 mg + 10 mg
NCT00525824 · Phase 3 · registry result, not featured evidence · combination
-23.5% (n=515) vs -11.2% (n=515) Atorva @ 6wk
NCT00418834 · Phase 3 · registry result, not featured evidence · combination
-20% (n=516) vs -15.8% (n=509) Atorva @ 12wk
NCT00418834 · Phase 3 · registry result, not featured evidence · combination
-54.65% (n=210) vs -49.93% (n=199) Simvastatin + Ezetimibe @ 6wk10 mg + 10 mg
NCT00525824 · Phase 3 · registry result, not featured evidence · combination
-21.32% (n=74) vs -2.25% (n=76) placebo @ 24wk
NCT01611883 · Phase 4 · registry result, not featured evidence
-22.675% (n=24) vs -1.322% (n=24) placebo @ 6wk
NCT00794677 · Phase 4 · registry result, not featured evidence
-55.4% (n=280) vs -55.2% (n=280) Ezetimibe and Atorvastatin @ 6wk
NCT01370603 · Phase 3 · registry result, not featured evidence
-25.47% (n=85) vs 0.28% (n=42) placebo @ 12wk
NCT00867165 · Phase 3 · registry result, not featured evidence
-22.54% (n=91) vs 1.64% (n=43) placebo @ 2wk
NCT00867165 · Phase 3 · registry result, not featured evidence
-24.94% (n=90) vs -0.33% (n=43) placebo @ 4wk
NCT00867165 · Phase 3 · registry result, not featured evidence
-25.41% (n=90) vs 1.14% (n=44) placebo @ 8wk
NCT00867165 · Phase 3 · registry result, not featured evidence
-23.3% (n=277) vs -9% (n=279) Atorvastatin @ 6wk
NCT00276484 · Phase 3 · registry result, not featured evidence · combination
-26.7% (n=92) vs -10.2% (n=92) Atorvastatin @ 6wk
NCT00276458 · Phase 3 · registry result, not featured evidence · combination
Total Cholesterol Change mg/dL 187 vs 219 placebo mg/dL @ 7wk
absolute change · mg/dL
NCT00701727 · Phase 4 · registry result, not featured evidence
Triglyceride Change mg/dL 121 vs 128 placebo mg/dL @ 7wk
absolute change · mg/dL
NCT00701727 · Phase 4 · registry result, not featured evidence
LDL-C 116 vs 148 placebo mg/dL @ 7wk
absolute change · mg/dL
NCT00701727 · Phase 4 · registry result, not featured evidence
HDL-C Change mg/dL 45 vs 46 placebo mg/dL @ 7wk
absolute change · mg/dL
NCT00701727 · Phase 4 · registry result, not featured evidence
Apo B -12.1% (n=120) vs -6.1% (n=479) Atorvastatin @ 6wk10 mg + 10 mg
percent change · % of baseline
NCT01154036 · Phase 3 · registry result, not featured evidence · combination
show 17 more results
-12% (n=124) vs -6.3% (n=124) Atorvastatin @ 12wk10 mg + 20 mg
NCT01154036 · Phase 3 · registry result, not featured evidence · combination
-14% (n=231) vs -6.3% (n=124) Atorvastatin @ 12wk10 mg + 20 mg
NCT01154036 · Phase 3 · registry result, not featured evidence · combination
-4% (n=27) vs -6.3% (n=124) Atorvastatin @ 12wk10 mg + 10 mg
NCT01154036 · Phase 3 · registry result, not featured evidence · combination
-42.6% (n=352) vs -43.3% (n=345) Ezetimibe and Atorvastatin @ 6wk10 mg/20 mg
NCT01370590 · Phase 3 · registry result, not featured evidence
-49.1% (n=248) vs -44.7% (n=239) placebo @ 12wk
NCT00639158 · Phase 3 · registry result, not featured evidence · combination
-49.5% (n=199) vs -41.95% (n=194) Simvastatin + Ezetimibe @ 6wk20 mg + 10 mg
NCT00525824 · Phase 3 · registry result, not featured evidence · combination
-16.8% (n=507) vs -7.7% (n=514) Atorva @ 6wk
NCT00418834 · Phase 3 · registry result, not featured evidence · combination
-14% (n=511) vs -10.8% (n=506) Atorva @ 12wk
NCT00418834 · Phase 3 · registry result, not featured evidence · combination
-46.11% (n=206) vs -41.95% (n=194) Simvastatin + Ezetimibe @ 6wk10 mg + 10 mg
NCT00525824 · Phase 3 · registry result, not featured evidence · combination
-17.99% (n=24) vs -2.577% (n=24) placebo @ 6wk
NCT00794677 · Phase 4 · registry result, not featured evidence
-48.7% (n=278) vs -48.3% (n=279) Ezetimibe and Atorvastatin @ 6wk
NCT01370603 · Phase 3 · registry result, not featured evidence
-21.66% (n=85) vs -1.42% (n=42) placebo @ 12wk
NCT00867165 · Phase 3 · registry result, not featured evidence
-17.8% (n=275) vs -7.7% (n=276) Atorvastatin @ 6wk
NCT00276484 · Phase 3 · registry result, not featured evidence · combination
-21.4% (n=89) vs -7.7% (n=90) Atorvastatin @ 6wk
NCT00276458 · Phase 3 · registry result, not featured evidence · combination
-31.62% (n=24) vs -1.17% (n=27) placebo @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
-34.75% (n=24) vs -0.9% (n=27) placebo @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
-29.73% (n=27) vs -0.11% (n=28) placebo @ 8wk
NCT04770389 · Phase 2 · registry result, not featured evidence · combination
LDL-C 106 vs 108.273 placebo mg/dL @ 6wk10 mg
absolute change · mg/dL
6 weeks post treatment
NCT00319449 · Phase 4 · registry result, not featured evidence

+ 21 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ezetimibe's landscape · Hyzetimibe's landscape